Skip to content

Spruce Biosciences Reports First Quarter 2021 Financial Results And Provides Corporate Updates

Presentation of Phase 2 Data of Tildacerfont at 23rd Annual European Congress of Endocrinology 

Cash and Cash Equivalents of $148.6 million

SAN FRANCISCO–(BUSINESS WIRE)–May 12, 2021– Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

“Throughout the first quarter of 2021, Spruce Biosciences made substantial progress in our efforts to advance new treatment options for people living with rare endocrine disorders and to maximize the potential of tildacerfont as a therapeutic to treat people living with classic congenital adrenal hyperplasia, or CAH, and other diseases impacted by ACTH,” said Richard King, Chief Executive Officer of Spruce Biosciences. “We continue to advance enrollment into our late-stage CAHmelia program in adult classic CAH and remain encouraged with the level of patient interest registered with our study investigators. Looking ahead, we remain on track to initiate our Phase 2 program in children with classic CAH in the second half of this year. In the pediatric classic CAH population, the imbalance between excess adrenal androgens and glucocorticoids can lead to irreversible impacts on childhood development. Tildacerfont has the potential to ease the disease and steroid burden for children, which may enable normal growth progression through childhood and adolescence.”

Corporate Highlights

  •  Presentation of Phase 2 Data of Tildacerfont at European Society of Endocrinology’s 23rd Annual European Congress of Endocrinology (ECE 2021): On May 24, 2021, Richard Auchus, MD, PhD, Professor of Internal Medicine and Pharmacology, University of Michigan, Ann Arbor, will present data from the company’s Phase 2 program of tildacerfont in classic CAH at ECE 2021. The presentation will highlight data from the company’s SPR001-202 clinical trial, which demonstrated the ability of tildacerfont to reduce and normalize key disease biomarkers over a 12-week period. Normalization of highly elevated hormones in classic CAH patients over a 12-week trial and without increases to daily steroid doses, to the company’s knowledge, has not been publicly reported with any other investigational product candidate to date.
  •  Cash and Cash Equivalents of $148.6 Million: Based on the company’s current operating plan, the company is well capitalized to advance its pipeline through key milestones, including primary data readout from its CAHmelia studies and initiation of Phase 2 programs in pediatric classic CAH and a rare form of polycystic ovary syndrome (PCOS).

Anticipated Upcoming Milestones

  •  Submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for PCOS in the first half of 2021, and initiation of a Phase 2 proof-of-concept clinical trial in the second half of 2021
  •  Initiation of a Phase 2 clinical program in pediatric classic CAH in the second half of 2021
  •  Results from CAHmelia-203 in adult classic CAH patients with poor disease control the first half of 2022
  •  Results from CAHmelia-204 in adult classic CAH patients with good disease control in the second half of 2022

First Quarter 2021 Financial Results

Cash and Cash Equivalents: Cash and cash equivalents as of March 31, 2021, were $148.6 million.

Research and Development (R&D) Expenses: R&D expenses for the first quarter ended March 31, 2021 were $6.7 million compared to $4.6 million for the same period in 2020. The overall increase in R&D expenses was primarily related to the advancement of tildacerfont into late-stage clinical development.

General and Administrative (G&A) Expenses: G&A expenses for the first quarter ended March 31, 2021 were $3.1 million compared to $0.5 million for the same period in 2020. The overall increase in G&A expenses was primarily driven by an increase in costs related to operation as a public company.

Total Operating Expenses: Total operating expensesfor the quarter ended March 31, 2021 were $9.8 million compared to $5.1 million for the same period in 2020. Stock-based compensation for the first quarter ended March 31, 2021 was $1.1 million. When excluding depreciation and stock-based compensation, total operating expenses for the quarter ended March 31, 2021 were $8.7 million.

Net Loss: Net loss for the three months ended March 31, 2021 was $9.9 million compared to $5.1 million for the same period in 2020.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States). To learn more, visit and follow us on Twitter @Spruce_BioLinkedInFacebook and YouTube.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Spruce’s clinical trials, the regulatory approval path for tildacerfont, the strength of Spruce’s balance sheet and the adequacy of Spruce’s cash position. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believe”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Use of Non-GAAP Financial Measures

Spruce has presented certain non-GAAP financial measures in this release. This release and the reconciliation tables included herein include non-GAAP total operating expenses and non-GAAP G&A expenses, both of which exclude depreciation and stock-based compensation. Spruce excludes depreciation and stock-based compensation because management believes the exclusion of these items is helpful to investors to evaluate Spruce’s recurring operational performance. Spruce management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an on-going basis, and internally for operating, budgeting and financial planning purposes. The non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

SPRUCE BIOSCIENCES, INC.CONDENSED BALANCE SHEETS(unaudited)(in thousands, except share amounts)
  March 31,2021  December 31,2020 
Current assets:        
Cash and cash equivalents $148,627  $157,150 
Prepaid expenses  2,687   2,971 
Other current assets  272   276 
Total current assets  151,586   160,397 
Restricted cash  216   216 
Right-of-use assets  1,716   1,793 
Other assets  473   477 
Total assets $153,991  $162,883 
Current liabilities:        
Accounts payable $2,566  $3,628 
Term loan, current portion     2,554 
Accrued expenses and other current liabilities  3,558   2,496 
Accrued compensation and benefits  727   1,085 
Total current liabilities  6,851   9,763 
Term loan, net of current portion  4,843   1,922 
Lease liability, net of current portion  1,566   1,653 
Other liabilities  8   118 
Total liabilities  13,268   13,456 
Stockholders’ equity:        
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2021 and December 31, 2020      
Common stock, $0.0001 par value, 200,000,000 shares authorized, 23,301,872 and 23,260,399 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively  2   2 
Additional paid-in capital  211,449   210,266 
Accumulated deficit  (70,728)  (60,841)
Total stockholders’ equity  140,723   149,427 
Total liabilities and stockholders’ equity $153,991  $162,883 
SPRUCE BIOSCIENCES, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except share and per share amounts)
  Three Months EndedMarch 31, 
  2021  2020 
Operating expenses:        
Research and development $6,714  $4,610 
General and administrative  3,103   523 
Total operating expenses  9,817   5,133 
Loss from operations  (9,817)  (5,133)
Interest expense  (89)  (74)
Other income, net  19   39 
Net loss $(9,887) $(5,168)
Net loss per share, basic and diluted $(0.42) $(6.76)
Weighted-average shares of common stock outstanding, basic and diluted  23,283,658   764,408 
SPRUCE BIOSCIENCES, INC.Reconciliation of Total Operating Expenses to Non-GAAP Total Operating Expenses(unaudited)(in thousands)
  Three Months Ended March 31, 
  2021  2020 
Operating expenses:        
Total operating expenses $9,817  $5,133 
Depreciation  4    
Stock-based compensation  1,120   32 
Non-GAAP total operating expenses $8,693  $5,101 
Reconciliation of G&A Expenses to Non-GAAP G&A Expenses(unaudited)(in thousands)
  Three Months Ended March 31, 
  2021  2020 
Operating expenses:        
G&A expenses $3,103  $523 
Depreciation  4    
Stock-based compensation  856   22 
Non-GAAP G&A expenses $2,243  $501 

Media Contact:
Will Zasadny
Canale Communications
(619) 961-8848

Xuan Yang
Solebury Trout
(415) 971-9412

Source: Spruce Biosciences